• linkedin
  • Increase Font
  • Sharebar

    Feminine Rejuvenation Market Growth Surges Via Energy-Based Devices


    Non-ablative 2940 nm Er:YAG-based systems utilize laser pulses to heat tissue to a depth of 100 microns, leading to contraction of these irradiated tissues and ultimately neocollagenesis, providing improvement in vaginal laxity. Top devices featuring Er:YAG technology include IntimaLase, RenovaLase and IncontiLase from Fotona (Europe & U.S.), one of the most established laser companies in the aesthetic industry. However in the U.S., Fotona currently does not offer these specific gynecologic options. Lutronic (Fremont, Calif.) has CE Mark clearance for their Action II Petit Lady, which runs on the multi-purpose Action II fractional Er:YAG laser. Currently it is only available outside of the U.S.

    The diVa™ hybrid fractional laser from Sciton (Palo Alto, Calif.) uniquely combines the 2940 ablative Er:YAG wavelength and 1470 nm to provide customizable treatments with tunable ablation and coagulation, varying densities and automated precision that rotates, retracts and delivers pulses automatically in 3 to 5 minutes. Choices of 90°, 180° and 360° angles are software driven. diVa rotates within the single-use quartz dilator (SQD), for uniform, uninterrupted energy delivery, and when used in combination with diVaTyte™, it is an easy, no downtime, external approach that offers a fast, comfortable and consistent solution for vaginal therapy, all from the JOULE™ platform.

    Monopolar RF has been utilized for rejuvenation of the skin as it allows for the safe delivery of thermal energy to the deep dermis to achieve lifting and tightening while avoiding epidermal and neurovascular damage. Treatment with RF initially produces immediate collagen fibril contraction and resultant tissue tightening to initiate a wound healing response that produces long-term neocollagenesis and tissue contraction. Examples of RF-based feminine rejuvenation systems include ThermiVa from Thermi, an Almirall Company (Irving, Texas), the Viveve system from Viveve, Inc. (Sunnyvale, Calif.), and the ULTRA Femme 360 system from BTL Aesthetics (Framingham, Mass.), which is the newest product to hit the market.

    BTL Ultra Femme 360 reportedly offers the shortest RF treatment time available for women’s intimate health and wellness procedures. Utilizing 360° volumetric heating and novel EFC™ technology with integrated impedance intelligence, this device ensures the most effective and uniform tissue heating, allowing physicians to treat at high energy levels without compromising patient comfort.

    Currently Hironic is the only manufacturer to offer a HIFU device to treat vaginal laxity and atrophy and has five patents pending for this technology related to gynecologic treatment. At this time the device is only available outside of the U.S.

    In 2016, there were an estimated 5,900 systems installed globally for feminine rejuvenation indications. These devices were used to perform over half a million procedures, generating about $512 million in fees for practitioners, according to the recently released Energy-Based Feminine Rejuvenation market study from Medical Insight, Inc. (Irvine, Calif.).

    Also, in 2016, total global sales of feminine rejuvenation devices exceeded $100 million, as reported by Medical Insight. Through 2021, sales are estimated to rise by 26% per year. On a regional basis, North America will be the largest market for energy-based feminine rejuvenation with growth expected to expand by 30% per year, followed by Asia at 24%, Europe at 20% and Latin America at approximately 16%.

    It is obvious that energy-based feminine rejuvenation services represent one of the most attractive and fastest growing new market sectors, and Patricia Scheller CEO at Viveve, Inc., believes the market for feminine rejuvenation, “Could easily surpass these current estimates as more and more women and physicians see the benefits of these procedures.”


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results